- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Prostate Cancer | Clinical
PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC
November 17, 2022
Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Clinical Commentary: Data to Consider When Sequencing Therapy in Castration-Resistant Prostate Cancer
November 15, 2022
At a live event discussing the case of a man, aged 75 years, with metastatic castration-resistant prostate cancer, Rana McKay, MD, focused on the makeup and results of the pivotal phase 4 CARD and phase 3 VISION studies.
The Impact of PSMA PET on Prostate Cancer Treatment
November 14, 2022
David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.
Percentage of Actionable Mutations in Prostate Cancer Underscores Importance of Testing
November 12, 2022
During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.
ADT Intensification With Docetaxel is the Standard mCSPC Treatment Strategy
November 11, 2022
According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.
The Latest Treatment Advances in Prostate Cancer
November 11, 2022
In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.
Roundtable Discussion: Selecting a Novel Hormonal Agent for Relapsed nmCRPC
November 10, 2022
During a Targeted Oncology case-based event, Alan H. Bryce, MD, discussed decision-making for treating a patient with non-metastatic castration-resistant prostate cancer.
Continuous Enzalutamide Proves Beneficial in Previously Treated mCRPC
November 09, 2022
Results from a phase 3 study show that the continuous maintenance therapy of enzalutamide reduces the risk of disease progression in certain patients with metastatic castration resistant prostate cancer.
About the EXTEND Trial of Patients With Oligometastatic Prostate Cancer
November 07, 2022
Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discusses the design of the randomized, phase 2, basket EXTEND trial.
FDA Approves Leuprolide Acetate Injection for Advanced Prostate Cancer
November 03, 2022
An abbreviated new drug application was approved by the FDA for leuprolide acetate injection as treatment of patients with advanced prostate cancer.